News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,554 Results
Type
Article (8043)
Company Profile (140)
Press Release (476466)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166783)
Career Advice (305)
Deals (25744)
Drug Delivery (7)
Drug Development (52891)
Employer Resources (14)
FDA (9762)
Job Trends (8574)
News (238247)
Policy (17916)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (488)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33160)
ALS (104)
Alzheimer's disease (974)
Antibody-drug conjugate (ADC) (262)
Approvals (10370)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6958)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (507)
Cancer (3628)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47849)
Collaboration (1239)
Commercialization (3)
Compensation (1449)
Complete response letters (34)
COVID-19 (756)
CRISPR (63)
C-suite (737)
Cystic fibrosis (85)
Data (5625)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4180)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73705)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87596)
Executive appointments (698)
FDA (12369)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (910)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (944)
Grass and pollen (2)
Guidances (281)
Healthcare (9317)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (156)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12393)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (505)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (528)
Marketing (8)
MASH (118)
Medical device (8650)
Medtech (8790)
Mergers & acquisitions (14378)
Metabolic disorders (704)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1818)
NextGen: Class of 2026 (3150)
Non-profit (841)
Obesity (223)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (502)
Peanut (31)
People (41217)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15461)
Phase 2 (21372)
Phase 3 (14393)
Pipeline (7235)
Policy (18)
Postmarket research (1570)
Preclinical (6551)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3019)
Recruiting (6)
Regulatory (14798)
Reports (20)
Research institute (586)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (318)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Last 7 days (457)
Last 30 days (1578)
Last 365 days (19025)
2026 (12075)
2025 (19254)
2024 (22997)
2023 (26548)
2022 (34610)
2021 (37185)
2020 (33502)
2019 (23291)
2018 (17470)
2017 (18766)
2016 (17918)
2015 (24263)
2014 (21680)
2013 (18137)
2012 (20221)
2011 (20441)
2010 (20333)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17884)
Australia (2097)
California (11914)
Canada (3127)
China (517)
Colorado (481)
Connecticut (407)
Delaware (207)
Europe (24624)
Florida (1780)
Georgia (375)
Hawaii (3)
Idaho (46)
Illinois (696)
India (48)
Indiana (314)
Iowa (14)
Japan (398)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1193)
Massachusetts (7825)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2610)
New Mexico (12)
New York (2811)
North Carolina (1267)
North Dakota (4)
Northern California (5961)
Ohio (276)
Oklahoma (14)
Oregon (18)
Pennsylvania (2244)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4949)
Tennessee (119)
Texas (1925)
United States (38686)
Utah (358)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (921)
West Virginia (1)
Wisconsin (73)
484,554 Results for "chromadex inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
June 2, 2026
·
7 min read
Business
ChromaDex Corporation Reports First Quarter 2024 Financial Results
ChromaDex Corp. announced financial results for the first quarter of 2024.
May 8, 2024
·
13 min read
ChromaDex to Join Russell 2000® Index
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research with a focus on healthy aging, announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.
July 1, 2024
·
6 min read
Biotech Beach
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
ChromaDex Corp. announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, June 11, 2024, at 2:00pm PST.
June 4, 2024
·
2 min read
Press Releases
ChromaDex to Present at the 37th Annual Roth Conference
March 12, 2025
·
3 min read
Press Releases
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol “NAGE” Effective March 19, 2025
March 13, 2025
·
3 min read
Business
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
ChromaDex Corp. announced financial results for the third quarter of 2023.
November 8, 2023
·
13 min read
Press Releases
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
March 4, 2025
·
18 min read
Biotech Beach
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
ChromaDex Corp. today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
May 23, 2024
·
2 min read
Business
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
ChromaDex Corp. announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024.
April 24, 2024
·
4 min read
1 of 48,456
Next
